State Street Corp cut its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 103,335,618 shares of the biopharmaceutical company's stock after selling 2,422,020 shares during the period. State Street Corp owned about 5.06% of Bristol Myers Squibb worth $6,448,143,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. Cornerstone Select Advisors LLC increased its position in shares of Bristol Myers Squibb by 7.8% during the 3rd quarter. Cornerstone Select Advisors LLC now owns 20,482 shares of the biopharmaceutical company's stock valued at $1,278,000 after purchasing an additional 1,482 shares during the last quarter. Hikari Tsushin Inc. lifted its position in Bristol Myers Squibb by 1.0% in the 3rd quarter. Hikari Tsushin Inc. now owns 81,929 shares of the biopharmaceutical company's stock worth $5,112,000 after buying an additional 788 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in Bristol Myers Squibb by 168.8% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,363 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 856 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Bristol Myers Squibb in the third quarter worth approximately $1,560,000. Finally, TIAA CREF Individual & Institutional Services LLC boosted its stake in Bristol Myers Squibb by 2.0% in the third quarter. TIAA CREF Individual & Institutional Services LLC now owns 85,567 shares of the biopharmaceutical company's stock worth $5,339,000 after buying an additional 1,688 shares in the last quarter. Institutional investors own 76.41% of the company's stock.
Trending Headlines about Bristol Myers Squibb
Here are a few of the latest headlines about BMY:
Analyst Upgrades and Downgrades
Several research firms have commented on BMY. HSBC reissued a "hold" rating and set a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. The Goldman Sachs Group raised shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 16th. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. Finally, Royal Bank Of Canada reiterated a "sector perform" rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $65.46.
Check Out Our Latest Analysis on Bristol Myers Squibb
Bristol Myers Squibb Price Performance
Shares of Bristol Myers Squibb stock opened at $58.81 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The business's 50 day simple moving average is $61.45 and its two-hundred day simple moving average is $60.44. The stock has a market capitalization of $120.22 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a one year low of $45.52 and a one year high of $68.64.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the previous year, the company posted $1.63 earnings per share. The business's revenue was up 6.9% on a year-over-year basis. Analysts forecast that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is currently 55.88%.
Insiders Place Their Bets
In other news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares of the company's stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company's stock.
About Bristol Myers Squibb
(
Free Report)
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.